Aegis Therapeutics, LLC' Intravail(R) Technology Provides Effective Oral Delivery Of Anti-Sense Drugs In Primates

SAN DIEGO, CA -- (MARKET WIRE) -- November 15, 2006 -- Aegis Therapeutics, a drug delivery technology company providing exceptionally high and unmatched bioavailability for non-invasive intranasal and transmucosal delivery of peptide, protein and other macromolecular drugs, today announced the results of a collaborative study confirming the effectiveness of its Intravail® transmucosal absorption enhancement agents in oral delivery of anti-sense drugs. Antisense drugs are members of an exciting new class of polynucleotide-based therapeutics that include siRNA, aptamers, and mirror-image aptamers (so-called Spiegelmers).

Back to news